<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">cn</journal-id>
<journal-id journal-id-type="coden">acncdm</journal-id>
<journal-title-group>
<journal-title>ACS Chemical Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1948-7193</issn>
<publisher>
<publisher-name>American Chemical
Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30829033</article-id>
<article-id pub-id-type="pmc">6639775</article-id>
<article-id pub-id-type="doi">10.1021/acschemneuro.8b00692</article-id>
<article-categories>
<subj-group>
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Chronic, Intermittent Microdoses of the Psychedelic <italic>N</italic>,<italic>N</italic>-Dimethyltryptamine (DMT) Produce
Positive Effects on Mood and Anxiety in Rodents</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="ath1">
<name>
<surname>Cameron</surname>
<given-names>Lindsay
P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">†</xref>
</contrib>
<contrib contrib-type="author" id="ath2">
<name>
<surname>Benson</surname>
<given-names>Charlie J.</given-names>
</name>
<xref ref-type="aff" rid="aff2">‡</xref>
</contrib>
<contrib contrib-type="author" id="ath3">
<name>
<surname>DeFelice</surname>
<given-names>Brian C.</given-names>
</name>
<xref ref-type="aff" rid="aff3">§</xref>
</contrib>
<contrib contrib-type="author" id="ath4">
<name>
<surname>Fiehn</surname>
<given-names>Oliver</given-names>
</name>
<xref ref-type="aff" rid="aff3">§</xref>
<xref ref-type="aff" rid="aff4">∥</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="ath5">
<name>
<surname>Olson</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="other" rid="cor1">*</xref>
<xref ref-type="aff" rid="aff2">‡</xref>
<xref ref-type="aff" rid="aff5">⊥</xref>
<xref ref-type="aff" rid="aff6">#</xref>
</contrib>
<aff id="aff1"><label>†</label>Neuroscience
Graduate Program, <institution>University of California,
Davis</institution>, 1544 Newton Ct, Davis, California 95618, <country>United States</country></aff>
<aff id="aff2"><label>‡</label>Department
of Chemistry, <institution>University of California,
Davis</institution>, One Shields Avenue, Davis, California 95616, <country>United States</country></aff>
<aff id="aff3"><label>§</label>West
Coast Metabolomics Center, <institution>University of
California, Davis</institution>, One
Shields Avenue, Davis, California 95616, <country>United States</country></aff>
<aff id="aff4"><label>∥</label>Biochemistry
Department, <institution>King Abdulaziz University</institution>, Jeddah, <country>Saudi-Arabia</country></aff>
<aff id="aff5"><label>⊥</label>Department
of Biochemistry &amp; Molecular Medicine, School of Medicine, <institution>University of California, Davis</institution>, 2700 Stockton Blvd, Suite 2102, Sacramento, California 95817, <country>United States</country></aff>
<aff id="aff6"><label>#</label>Center for
Neuroscience, <institution>University of California,
Davis</institution>, 1544 Newton Ct, Davis, California 95618, <country>United States</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>E-mail: <email>deolson@ucdavis.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<day>17</day>
<month>07</month>
<year>2019</year>
</pub-date>
<volume>10</volume>
<issue>7</issue>
<issue-title>Serotonin Research 2018</issue-title>
<fpage>3261</fpage>
<lpage>3270</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>02</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 American Chemical Society</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Chemical Society</copyright-holder>
<license license-type="editor-choice">
<license-p>This is an open access article published under an ACS AuthorChoice <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html" xmlns:xlink="http://www.w3.org/1999/xlink">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p>
</license>
</permissions>
<abstract>
<p content-type="toc-graphic">
<graphic id="ab-tgr1" xlink:href="cn-2018-006929_0007" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</p>
<p>Drugs
capable of ameliorating symptoms of depression and anxiety
while also improving cognitive function and sociability are highly
desirable. Anecdotal reports have suggested that serotonergic psychedelics
administered in low doses on a chronic, intermittent schedule, so-called
“microdosing”, might produce beneficial effects on mood,
anxiety, cognition, and social interaction. Here, we test this hypothesis
by subjecting male and female Sprague Dawley rats to behavioral testing
following the chronic, intermittent administration of low doses of
the psychedelic <italic>N</italic>,<italic>N</italic>-dimethyltryptamine
(DMT). The behavioral and cellular effects of this dosing regimen
were distinct from those induced following a single high dose of the
drug. We found that chronic, intermittent, low doses of DMT produced
an antidepressant-like phenotype and enhanced fear extinction learning
without impacting working memory or social interaction. Additionally,
male rats treated with DMT on this schedule gained a significant amount
of body weight during the course of the study. Taken together, our
results suggest that psychedelic microdosing may alleviate symptoms
of mood and anxiety disorders, though the potential hazards of this
practice warrant further investigation.</p>
</abstract>
<kwd-group>
<kwd>Psychedelic</kwd>
<kwd>microdosing</kwd>
<kwd>DMT</kwd>
<kwd>depression</kwd>
<kwd>PTSD</kwd>
<kwd>anxiety</kwd>
<kwd>subhallucinogenic</kwd>
<kwd>neural plasticity</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>document-id-old-9</meta-name>
<meta-value>cn8b00692</meta-value>
</custom-meta>
<custom-meta>
<meta-name>document-id-new-14</meta-name>
<meta-value>cn-2018-006929</meta-value>
</custom-meta>
<custom-meta>
<meta-name>ccc-price</meta-name>
<meta-value></meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>